Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Dusan Merta"'
Publikováno v:
Harm Reduction Journal, Vol 18, Iss 1, Pp 1-9 (2021)
Abstract Background Intravenous drug use (IVDU) represents the major factor of HCV transmission, but the treatment uptake among people who inject drugs (PWID) remains low owing to a false presumption of low efficacy. The aim of our study was to asses
Externí odkaz:
https://doaj.org/article/39244e93a5f04f92a1ddd9df35d42d17
Publikováno v:
Life, Vol 13, Iss 4, p 932 (2023)
Background and objectives: HCV infection often remains untreated in people who inject drugs (PWID), albeit they may present with advanced liver fibrosis at a young age. We aimed to assess the rate of patients with significant fibrosis in PWID startin
Externí odkaz:
https://doaj.org/article/09030904c3aa4ad69be3c5328b700d61
Publikováno v:
Medicina, Vol 59, Iss 4, p 752 (2023)
Background and objectives: Recently, rapid progress has been made in the development of noninvasive methods for liver fibrosis assessment. The study aimed to assess the correlation between LSM and serum fibrosis markers to identify patients with adva
Externí odkaz:
https://doaj.org/article/50a2b0468109450fb99f05d81ac217a6
Publikováno v:
Kidney & Blood Pressure Research, Vol 43, Iss 2, Pp 594-605 (2018)
Background/Aims: Chronic hepatitis C (HCV) virus infection reactivates under immunosuppressive drugs and therefore has a negative impact on long-term survival of kidney transplant recipients. Treatment-induced clearance of hepatitis C virus (HCV) in
Externí odkaz:
https://doaj.org/article/eb14cc8f477340b582de8283135f6fa9
Autor:
Zuzana Rabekova, Sona Frankova, Milan Jirsa, Magdalena Neroldova, Mariia Lunova, Ondrej Fabian, Martin Kveton, David Varys, Klara Chmelova, Vera Adamkova, Jaroslav A. Hubacek, Julius Spicak, Dusan Merta, Jan Sperl
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 19, p 10560 (2021)
Heterozygotes for Z or S alleles of alpha-1-antrypsin (AAT) have low serum AAT levels. Our aim was to compare the risk of hepatocellular carcinoma (HCC) in patients with liver cirrhosis carrying the SERPINA1 MM, MZ and MS genotypes. The study groups
Externí odkaz:
https://doaj.org/article/49eab070c381406e9edb45a152ff0b01
Autor:
Renata Senkerikova, Sona Frankova, Milan Jirsa, Miluse Kreidlova, Dusan Merta, Magdalena Neroldova, Klara Chmelova, Julius Spicak, Jan Sperl
Publikováno v:
PLoS ONE, Vol 14, Iss 9, p e0222609 (2019)
BackgroundPNPLA3 rs738409 minor allele c.444G represents a risk factor for liver steatosis and fibrosis progression also in chronic hepatitis C (HCV). We investigated its impact on the timing of liver transplantation (LT) in patients with genotype 1b
Externí odkaz:
https://doaj.org/article/3b0996b9ca494923bf7c4a5439c5a4a7
Publikováno v:
Harm Reduction Journal, Vol 18, Iss 1, Pp 1-9 (2021)
Harm Reduction Journal
Harm Reduction Journal
Background Intravenous drug use (IVDU) represents the major factor of HCV transmission, but the treatment uptake among people who inject drugs (PWID) remains low owing to a false presumption of low efficacy. The aim of our study was to assess treatme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e63365097aa904e9957141a868bbb8d
https://doaj.org/article/39244e93a5f04f92a1ddd9df35d42d17
https://doaj.org/article/39244e93a5f04f92a1ddd9df35d42d17
Autor:
Julius Spicak, Jan Šperl, Sona Frankova, Dusan Merta, Klara Chmelova, Milan Jirsa, Magdalena Neroldova, Miluse Kreidlova, Renata Senkerikova
Publikováno v:
PLoS ONE
PLoS ONE, Vol 14, Iss 9, p e0222609 (2019)
PLoS ONE, Vol 14, Iss 9, p e0222609 (2019)
BackgroundPNPLA3 rs738409 minor allele c.444G represents a risk factor for liver steatosis and fibrosis progression also in chronic hepatitis C (HCV). We investigated its impact on the timing of liver transplantation (LT) in patients with genotype 1b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3ae8f955e87cebd23d303493351df67
https://pubmed.ncbi.nlm.nih.gov/31527889
https://pubmed.ncbi.nlm.nih.gov/31527889
Autor:
Renata Senkerikova, Eva Sticova, Klara Chmelova, Magdalena Neroldova, Dusan Merta, Pavel Trunecka, Sona Frankova, Milan Jirsa, Julius Spicak, Jan Šperl
Publikováno v:
Transplant infectious disease : an official journal of the Transplantation SocietyREFERENCES. 21(4)
BACKGROUND Cytomegalovirus (CMV) disease represents a serious complication in liver transplant (OLT) recipients. CMV prophylaxis reduces incidence of CMV disease in the early post-transplant period (on-prophylaxis disease, OPD) but may postpone its m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fec0817497f08011215c4c37c3752b9
https://pubmed.ncbi.nlm.nih.gov/31165537
https://pubmed.ncbi.nlm.nih.gov/31165537
Publikováno v:
Therapeutics and Clinical Risk Management
Jan Sperl,1 Sona Frankova,1 Miluse Kreidlova,2 Dusan Merta,3 Monika Tothova,4 Julius Spicak1 1Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, 2Institute of Medical Biochemistry and Laboratory Medicine, General
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46aa6099a9c605c7b5d8bf4c67367fb5
https://www.dovepress.com/combination-of-sofosbuvir-and-daclatasvir-in-the-treatment-of-genotype-peer-reviewed-article-TCRM
https://www.dovepress.com/combination-of-sofosbuvir-and-daclatasvir-in-the-treatment-of-genotype-peer-reviewed-article-TCRM